New Treatment for Certain Bacterial Pneumonia Receives FDA Approval – APhA submits compounding comments to FDA.

3Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

New Treatment for Certain Bacterial Pneumonia Receives FDA Approval – APhA submits compounding comments to FDA. – (866) 348-2889.

Officials with the FDA have approved a new indication for ceftolozane and tazobactam combination (Zerbaxa, Merck) drug. The new approval indicates the medication for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients age 18 years and older.

Ceftolozane and tazobactam was initially approved by the FDA in 2014 for treating complicated intra-abdominal infections and for complicated urinary tract infections.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.